

1 **Clinical and epidemiological characteristics of Madariaga and Venezuelan equine**
2 **encephalitis virus infections**

3
4 Luis Felipe Rivera^{1,2+}, Carlos Lezcano-Coba^{1,2+}, Josefrancisco Galué^{1,2}, Xacdiel Rodriguez^{1,2},
5 Yelissa Juarez^{1,2}, William M. de Souza³, Zeuz Capitan-Barrios^{2,4}, Anayansi Valderrama^{1,2}
6 Leyda Abrego^{1,2,4}, Hector Cedeño⁵, Carmela Jackman⁵, Jesse J. Waggoner⁶, Patricia V.
7 Aguilar⁷, Hilda Guzman⁷, Scott C. Weaver⁷, Robert B. Tesh⁷, Sandra López-Vèrges¹, Christl
8 A. Donnelly⁸, Cassia F. Estofolete⁹, Mauricio L. Nogueira^{7,9}, Nuno R. Faria^{10,11}, Nikos
9 Vasilakis⁷, Amy Y. Vittor^{*12}, Darci R. Smith^{*13}, Jean-Paul Carrera^{1,2,8*}

10
11
12 1. Instituto Conmemorativo Gorgas de Estudios de la Salud, Panama City, Panama

13 2. Carson Centre for Research in Environment and Emerging Infectious Diseases, La
14 Peñita, Darién, Panama

15 3. University of Kentucky, College of Medicine, Lexington, Kentucky, USA

16 4. Universidad de Panamá, Ciudad de Panamá

17 5. Ministry of Health, Panama City, Panama

18 6. Emory University, Atlanta, Georgia, USA

19 7. The University of Texas Medical Branch, Galveston, TX, USA

20 8. University of Oxford, Oxford, United Kingdom

21 9. Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo
22 Brazil

23 10. Imperial College London, London, United Kingdom

24 11. Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

25 12. University of Florida, Gainesville, Florida, USA

26 13. Naval Medical Research Command, Ft. Detrick, MD, USA

27
28
29
30 Keywords: Madariaga Virus, Venezuelan equine encephalitis, alphaviruses, outbreak
31 investigation

32
33 +equally contribution

34
35 *Address correspondence to: Jean-Paul Carrera, University of Oxford, Oxford, UK, OX1

36 3SY. Email: jean.carrera@biology.ox.ac.uk, or Instituto Conmemorativo Gorgas de Estudios
37 de la Salud, Panama City, Panama. Email: jpcarrera@gorgas.gob.pa,

38 Darci R. Smith, darci.smith.civ@health.mil, Naval Medical Research Command; Ft. Detrick,
39 MD

40 Amy Y. Vittor, Amy.Vittor@medicine.ufl.edu, University of Florida, Gainesville Florida

41

42 **Abstract.** Madariaga virus (MADV) and Venezuelan equine encephalitis virus (VEEV) are
43 emerging arboviruses affecting rural and remote areas of Latin America. However, there are
44 limited clinical and epidemiological reports available, and outbreaks are occurring at an
45 increasing frequency. We addressed this gap by analyzing all the available clinical and
46 epidemiological data of MADV and VEEV infections recorded since 1961 in Panama. A total
47 of 168 of human alphavirus encephalitis cases were detected in Panama from 1961 to 2023.
48 Here we describe the clinical signs and symptoms and epidemiological characteristics of
49 these cases, and also explored signs and symptoms as potential predictors of encephalitic
50 alphavirus infection when compared to those of other arbovirus infections occurring in the
51 region. Our results highlight the challenges clinical diagnosis of alphavirus disease in
52 endemic regions with overlapping circulation of multiple arboviruses.

53

54 **Introduction**

55 Arthropod-borne viruses (arboviruses) infect humans worldwide and cause significant
56 morbidity and mortality. During the past few decades, the emergence and/or resurgence of
57 arboviruses has been increasing to near pandemic proportions and poses a significant
58 global health threat (1). United States (U.S.) military personnel are frequently stationed in
59 areas where these viruses are endemic or where they may emerge, which could threaten
60 military readiness. Latin America is known to be endemic for several arboviruses that pose
61 significant public health concerns. Important alphaviruses in neotropical regions that can
62 cause human disease include Mayaro virus (MAYV), Venezuelan equine encephalitis virus
63 (VEEV), eastern equine encephalitis virus (EEEV), Madariaga virus (MADV; previously
64 considered a subtype of EEEV) and chikungunya virus (CHIKV), while important flaviviruses
65 include dengue virus (DENV), yellow fever virus (YFV) Zika virus (ZIKV), and St. Louis
66 encephalitis virus (SLEV) (2, 3).

67

68 VEEV is widely distributed throughout the Americas and at least 14 subtypes and varieties
69 have been described (4). VEEV subtypes IAB and IC can cause explosive, large-scale
70 epizootics in horses and spillover epidemics in humans (5, 6). VEEV enzootic subtypes (i.e.,
71 VEEV ID, IE) are associated with a regular incidence of human infections by spillover from
72 enzootic cycles that involve rodents and sylvatic mosquitoes. Evidence suggests that
73 equine-adaptive or mosquito-adaptive mutations in the VEEV enzootic subtype ID led to the
74 emergence of epizootic/epidemic VEEV subtypes (5). VEEV enzootic/endemic subtype ID
75 infection is highly prevalent in the eastern province of Darien, Panama, where human
76 infections are sometimes fatal and seroprevalence in some villages is up to 75% of the
77 population (5). Eastern equine encephalitis virus (EEEV) was reclassified as two different
78 species in 2010: EEEV in North America and MADV in Latin America (7). MADV was not

79 associated with human outbreaks before 2010 when the first known human outbreak was
80 reported in Darien, Panama (8). Both MADV and VEEV circulated simultaneously during this
81 outbreak with 99 acute cases and 19 hospitalizations for encephalitis. Confirmed cases
82 included 13 for MADV, 11 for VEEV, and one case of co-infection. A fatal MADV infection
83 was confirmed in this same region in 2017. Modelling of 2012 and 2017 Darien Province
84 serosurvey data suggested that alphavirus transmission is endemic in this region (9). Many
85 alphavirus disease cases appear to present as a self-limited febrile illness, but persistent
86 neurological signs and symptoms have been reported for up to five years following MADV
87 and VEEV exposure (5).

88

89 VEEV and MADV infections are likely underdiagnosed due to the lack of available diagnostic
90 tools and the inability to clinically differentiate them from other arboviral diseases. It is
91 estimated that up to 10% of dengue cases in Central and South America may actually be
92 due to VEEV (10). Complicating this further is the increasing trend in dengue incidence over
93 the last several decades (11). CHIKV and ZIKV had not previously circulated within the
94 Western Hemisphere until they emerged explosively in 2013 and 2014, respectively. Both
95 viruses became endemic in Latin America where they now co-circulate in DENV-endemic
96 regions (3). The clinical presentation of these arboviral diseases can range from
97 asymptomatic or undifferentiated mild febrile illness to severe disease (3).

98

99 The increasing geographical spread and disease incidence of arbovirus infections in the
100 Americas is a major public health concern. Undifferentiated febrile illnesses remain a
101 diagnostic and therapeutic challenge in arbovirus-prone regions, due to the lack of available
102 tools for the high diversity of pathogens responsible for these clinical syndromes. MADV and
103 VEEV have been associated with severe or even fatal outcomes, but early after disease
104 onset, these infections are often clinically indistinguishable from other arboviral syndromes,
105 delaying prompt care for patients at risk for more serious outcomes. Here we describe the
106 clinical signs/symptoms and epidemiological characteristics of all reported MADV and VEEV
107 human infections occurring in Panama from 1961-2023. Additionally, we explore potential
108 symptoms as predictors of encephalitic alphavirus infection when compared to those
109 occurring from other arbovirus infections endemic to the region.

110

111

112 **Materials and Methods**

113

114 **Ethics statement**

115 The use of human data and samples from outbreaks was approved by the Panamanian
116 Ministry of Health (protocol number 2077, protocol: 365/CBI/ICGES/2023, approved on

117 November 30, 2023), and the Gorgas Memorial Institute (GMI) IRB (protocol:
118 335/CBI/ICGES/21, protocol: 073/CBI/ICGES/21 and protocol 138/CBI/ICGES/22, approved
119 on March 19, 2021).

120

121 **Alphavirus surveillance**

122 Upon suspecting MADV or VEEV (henceforth called encephalitic alphavirus infection), health
123 center clinicians submit blood samples to Instituto Conmemorativo de Gorgas de Estudios
124 de la Salud (ICGES), which serves as the National Reference Center for Infectious Disease
125 Diagnostics in Panama. Alphavirus infections are also often identified through the National
126 Dengue Surveillance system or during encephalitis outbreak response activities. The former
127 system, instituted in 1988, initially provided centralized testing of dengue suspected cases
128 submitted by clinicians (1993 – 2009), but subsequently established diagnostic capacity in all
129 local clinical units (12). Some alphavirus infections were identified upon ruling out DENV
130 cases. In addition, several alphavirus outbreak investigations have been conducted since
131 2010 and consist of community-wide febrile surveillance and serosurveys.

132

133 **Alphavirus outbreak case definition**

134 The case definition of a suspected alphavirus encephalitis case included fever and
135 headache, while a probable case was defined as a suspected case with neurological
136 manifestations (e.g., somnolence, lethargy, or seizures). A confirmed case was defined as a
137 suspected or probable case with laboratory confirmation (i.e., viral isolation, RT-PCR, IgM
138 ELISA, or IgG ELISA or PRNT seroconversion of paired clinical samples). The general
139 laboratory algorithm for diagnosis is depicted in Figure 1 and detailed information of
140 laboratory procedures is provided in the supplemental material.

141

142 **Alphavirus data collection**

143 We retrospectively searched and retrieved clinical and epidemiological information of all
144 MADV and VEEV infections reported in clinical records and epidemiological forms from 1961
145 to 2020, available at ICGES, and extending data published previously (13). Cases detected
146 from 2021 to 2023, were collected as part of the surveillance initiative undertaken by the
147 USA-National Institute of Allergy and Infectious Diseases, Centers for Research in Emerging
148 Infectious Diseases Network initiative. The Coordinating Research on Emerging Arboviral
149 Threats Encompassing the Neotropics (CREATE-NEO) in Panama and the Armed Forces
150 Health Surveillance Division (AFHSD), Global Emerging Infections Surveillance (GEIS)
151 Branch, ProMIS ID P0052_23_NM undertakes acute febrile surveillance across the country.
152 The dataset includes demographic characteristics, clinical symptoms, severity of infection,
153 and sick contacts. When available, geographic coordinates of alphavirus-positive
154 households were also collected. Duplicate or similar signs and symptoms were condensed

155 into composite variables, which provided a better representation of the symptomatology.
156 These were then used to compare clinical manifestations across the main arboviral
157 infections in Panama (MADV, VEEV, DENV, CHIKV, ZIKV).

158

159 **Comparison of arboviral symptoms**

160 To account for low statistical power, confirmed MADV and VEEV infections were grouped
161 into a single category. Encephalitic alphavirus cases were defined as all laboratory-
162 confirmed alphavirus infections reported in Panama from 1961 to 2023. Encephalitic
163 alphavirus infections were compared to DENV, ZIKV and CHIKV. A DENV dataset was
164 obtained from a cross-sectional study in 2009 and a ZIKV dataset in 2016. Both DENV and
165 ZIKV datasets were provided by the São José do Rio Preto Health Service in São Paulo
166 State, Brazil, and were published elsewhere (14). The CHIKV data were obtained from
167 CHIKV surveillance in the state of Amazonas, and the City of Recife, Pernambuco, Brazil,
168 from 2015-2020 (15). Additional details of source, laboratory procedures and information of
169 controls are provided in the supplemental material. A flow chart of the alphavirus and
170 endemic arbovirus infections used in this study is depicted in Supplemental Figure 1.

171

172 **Statistical methods**

173 Initially, a total of 121 variables associated with participants' symptomatology were included
174 in the database. These variables underwent categorization and grouping based on specific
175 clinical criteria for each virus. Data were reduced using exploratory factor analysis (EFA) and
176 Principal component analysis (PCA). Variables with zero variance were excluded, using a
177 Kaiser-Meyer-Olkin threshold of 0.6 (Supplemental Table 1). Ultimately, sign and symptoms
178 were reduced to 14 variables, which were used in the analysis.

179

180 To evaluate MADV- and VEEV-associated signs and symptoms, we conducted multivariable
181 logistic regression analysis, controlling for age and biological sex. Univariate logistic
182 regressions were undertaken to evaluate the symptoms associated with alphavirus infection
183 (MADV and VEEV) and those reported in DENV-, ZIKV- and CHIKV infections. Variables
184 were selected using a nested log-likelihood ratio test. Variables with more than 10% missing
185 data were excluded from the final analysis. The associations between specific symptoms
186 and viral infection were expressed as odd ratios. A p-value of <0.05 was considered
187 statistically significant. Statistical analyses were undertaken using Stata v.17 and R Studio
188 statistical packages (Statacorp, College Station, TX).

189

190

191 **Results**

192

193 **MADV and VEEV epidemiology**

194 Between 1961 and 2023, Panama recorded 168 laboratory confirmed MADV and/or VEEV
195 infections. For VEEV infections, there were 131 confirmed cases, with 60 (45.8%) detected
196 during outbreaks and 71 (54.2%) identified through arbovirus surveillance (Figure 2A). For
197 MADV infections, 37 were confirmed cases, with 34 (91.9%) identified during outbreaks and
198 3 (8.1%) detected through passive arbovirus surveillance (Figure 2B). The socio-
199 demographic characteristics of these cases are described in Table 1. Detailed clinical and
200 epidemiological information was accessible for 132 out of 168 (78.6%) human alphavirus
201 encephalitis infections, comprising 36 MADV infections (27.2%) and 96 VEEV infections
202 (72.7%). The breakdown of age distribution for MADV cases revealed that 16 (44.4%) were
203 in the 0–5-year-old age group, 11 (30.6%) in the 6–20-year-old age group, and 9 (25.0%)
204 were in the ≥21-year-old age group. In VEEV infections, 16 (18.0%) cases were in the 0-5-
205 year-old age group, 35 (39.3%) were in the 6–20-year-old age group, and 38 (42.7%) were
206 in the ≥21-years old age group. Seven cases did not record age information (Table 1).

207

208 All human MADV infections were reported from the Darien province. VEEV infections were
209 reported throughout Panama, but most reports (63.4%) were also from the Darien Province
210 (Figure 3). The peak of MADV cases occurred during the 2010 outbreak in the Darien
211 Province, registering 13 laboratory-confirmed cases. The highest number of VEEV cases
212 occurred in 2015 (n=28) (Figure 2). Among the MADV cases, 23 were male and 13 were
213 female. Three cases exhibited mild disease, 11 were moderate, and 17 had severe
214 manifestations, resulting in a mild-to-severe ratio of 3:17. Only 56 VEEV infections had
215 recorded sex information, with a distribution of 39 male and 17 female cases. Severity
216 assessment was only possible in 45 VEEV cases due to incomplete clinical data, of which 10
217 cases (22.2%) were classified as mild, 25 (55.6%) as moderate, and 10 (22.2%) as severe,
218 resulting in a mild to severe ratio of 1:1. One MADV fatality (1/36, 2.8%), and 8 VEEV
219 fatalities (8/95, 8.4%) were reported.

220

221 **MADV and VEEV laboratory testing**

222 We conducted a retrospective analysis to identify the diagnostic methods employed for
223 detecting VEEV and MADV infections from 1961 to 2023. MADV infections were identified
224 nearly exclusively (n=26, 91.9%) by ELISA IgM, with a single case (8.1%) detected by RT-
225 PCR on brain tissue following autopsy. VEEV infections were mostly identified through viral
226 isolation (n=67, 51.1%), followed by ELISA IgM (n=45, 34.3%), and RT-PCR (n=19, 14.5%)
227 (Supplemental Table 2).

228

229 **VEEV and MADV clinical presentation**

230 The most frequently documented signs/symptoms of MADV infections included fever (n=29,
231 81.0%), neurological symptoms (n=20, 55.6%), headache (n=15, 41.7%), and vomiting
232 (n=15, 41.7%). Fever (n=76, 87.3%), headache (n=51, 58.6%), and vomiting (n=27, 28.1%),
233 were predominantly present in VEEV positive cases. Overall, neurological symptoms were
234 more common in MADV infections, and slightly more common among males. Less common
235 signs/symptoms, including diarrhea (n=8, 9.2%), pharyngitis (n=2, 2.3%), hemorrhage (n=2,
236 2.3%), and rash (n=1, 1.1%) were more prevalent in VEEV infections (Figure 4).

237

238 Fever was consistently reported among both viruses, both sexes and amongst all age
239 groups (Figure 5 and 6). Headaches were also consistently reported in patients infected by
240 both viruses but increased in frequency concurrently with age. In MADV cases, there was an
241 overall higher frequency of neurological symptoms consistently seen in the 0-5 and 6-20 age
242 groups, which contrasts with VEEV infections, where neurological symptoms were reported
243 in the >5-year-old age group. The frequency of neurological symptoms was also higher in
244 males for MADV infections (61% for males vs 45% for females), but equally distributed
245 among VEEV cases (20% for males vs. 19% for females) (Figure 5). Myalgias, arthralgias,
246 and nausea were more commonly seen in VEEV cases, and their frequency also increased
247 with age, with the highest frequency reported in the ≥21-year-old age group (Figure 6).
248 Abdominal pain was only reported amongst VEEV cases and was more commonly reported
249 in females and exclusively reported in the ≥21-year-old age group. Conjunctivitis was
250 exclusively seen in the ≥21-year-old age group for MADV infections. Interestingly, diarrhea
251 was equally distributed among VEEV cases of both sexes until age 20, with only male cases
252 reporting diarrhea in the ≥21-year-old age group.

253

254 Logistic regression analysis controlling for sex and age showed that seizures and vomiting
255 were associated with MADV infections to a greater extent than VEEV infections
256 (Supplemental Table 3). At the multivariable level, after variable selection processes, only
257 seizures remained statistically significant when comparing MADV and VEEV (Figure 7A,
258 Supplemental Table 3).

259

260 **Encephalitic alphavirus versus DENV infection**

261 When alphavirus infection was compared to DENV infection at the univariate level, patients
262 with MADV and VEEV infections were less likely to present with abdominal pain, mucosal
263 bleeding, headaches, myalgias or nausea, while respiratory symptoms, seizures, vomiting,
264 and diarrhea were more frequent in alphavirus infections (Supplemental Table 4).

265 At the multivariable level, abdominal pain, headache, and myalgias remained less frequent
266 in alphavirus compared to dengue infection, while arthralgia and vomiting remained more
267 frequently associated with alphavirus infection (Figure 7B).

268

269 **Encephalitic alphavirus versus ZIKV infection**

270 When alphavirus infection was compared with ZIKV infection at the univariate level, patients
271 with MADV and VEEV infections were less likely to present with respiratory symptoms,
272 pharyngitis, headaches, arthralgias, myalgias, and conjunctivitis, while fever, seizures, and
273 vomiting were more frequent (Supplemental Table 5). At the multivariable level, arthralgia
274 and myalgias were less frequent in alphavirus infection, while fever and vomiting were more
275 common (Figure 7C).

276

277 **Encephalitic alphavirus versus CHIKV infection**

278 Univariate analysis of alphavirus infection compared with CHIKV infection showed that fever,
279 respiratory symptoms, headaches, arthralgias, myalgias were less common in encephalitic
280 alphavirus infection, while pharyngitis, diarrhea, and vomiting were more common
281 (Supplemental Table 6). At the multivariable level, arthralgia and myalgia were less frequent
282 in alphavirus infection, and nausea and vomiting were more common (Figure 7D).

283

284 **Discussion**

285

286 In this epidemiological study, we have provided a comprehensive assessment of VEEV and
287 MADV cases in Panama. We summarize and contextualize the clinical findings of human
288 cases of MADV and VEEV in Panama, and identified symptoms that could be used as
289 suggestive of MADV and VEEV infection when compared to other endemic arboviral
290 infections in the region. We have shown that MADV and VEEV cases disproportionately
291 affected males, and MADV occurs more often in children while most VEEV cases occur in
292 adults.

293

294 It is unclear if the sex or age-related susceptibility differences of VEEV and MADV are due to
295 a lack of pre-existing immunity, or different exposure risks (e.g., occupational). VEEV has
296 been present in Panama since the mid-20th century when the first human isolate was made
297 in 1961 (16). The first human outbreak of VEEV in Panama occurred in 1967 in U.S soldiers
298 training on the western shores of Gatun Lake (17). Since then, outbreaks of VEEV have
299 been reported periodically in humans. While equine cases of MADV have been documented
300 in Panama since 1936 (18), instances of human cases were infrequent before 2010, despite
301 active human surveillance during outbreaks and widespread mosquito isolations (10, 19, 20).

302 A 2012 study on the MADV and VEEV seropositivity in humans demonstrated an increasing
303 prevalence of antibodies for VEEV with age demonstrating that the virus is endemic in the
304 region (21). This same trend was not observed for MADV suggesting that the virus recently
305 emerged in humans during the 2010 outbreak. MADV may have gained human virulence
306 since 2010 (8) which may explain why we continue to see human cases. Children may be
307 more susceptible to MADV due to a lack of pre-existing immunity or an immature immune
308 system. The primary risk factors for human exposure to both viruses were found to be
309 farming and fishing (21). Perhaps males spend more time outside performing these activities
310 which puts them at an increased risk for exposure to infected mosquitoes. Our results
311 highlight the need for continued surveillance for VEEV and MADV to better understand these
312 differences.

313

314 The Darien province in Panama is a hotspot for VEEV and MADV activity, especially for
315 more recent outbreaks. All MADV human infections have occurred in this region whereas
316 VEEV infections have occurred throughout Panama. Darien is a remote region in eastern
317 Panama near the Colombian border that is inhabited primarily by Indigenous communities.
318 This region contains swamps and forest habitats that can support the enzootic transmission
319 cycle of VEEV and MADV involving rodents and mosquitoes. The Darien region also has a
320 high number of refugee and migrant crossings with over 500,000 reported by the United
321 Nations in 2023 (22). Human migration through this region could result in more cases and
322 the potential spread to other regions. This is highlighted by the MADV cases detected
323 outside Darien, which were reported by members of the border police working in the Darien
324 Province, but symptoms did not develop until they returned to their home regions. While our
325 study reports 168 confirmed human cases of encephalitic alphavirus infection in Panama,
326 the true burden of disease is likely underestimated which is highlighted by the recent finding
327 that 11.9% of dengue-like disease patients were VEEV infections (23).

328

329 As described previously throughout the range of enzootic strains, the majority of human
330 VEEV infections in Panama were symptomatic, and reported symptoms included fever,
331 headache, chills, and arthralgia (10). We observed similar symptoms in our study where
332 fever, headache, nausea, and vomiting were frequently reported. Seizures occurred in 10%
333 of cases which is similar to previous reports [reviewed in (24, 25)]. During the 2010 outbreak
334 of MADV, reported symptoms included fever, headache, vomiting, and diarrhea followed by
335 progression to a neurological disease similar to that observed for EEEV (8). The current
336 study found that fever, vomiting, and seizure were the most reported symptoms. Seizures
337 occurred in 42.8% of cases which is significantly higher compared to 10% for VEEV. Most
338 encephalitic alphavirus infections present as a self-limiting febrile illness, but neurological

339 sequelae following recovery from alphavirus infection has been documented at high rates for
340 VEEV and EEEV (50-90%), with individuals reporting one or more long-term symptoms (5,
341 25). Interestingly, these individuals did not recall having encephalitis or severe neurological
342 signs/symptoms. This suggests that long-term neurological sequelae occur even after mild to
343 moderate clinical presentations. Therefore, the development of any signs of neurologic
344 disease or sequelae should be an important indication of encephalitic alphavirus infection
345 and monitored closely.

346

347 In our study vomiting was positively associated with encephalitic alphavirus infection when
348 compared to other arboviruses. Vomiting can occur due to elevated intracranial pressure,
349 which in turn is seen in acute viral encephalitis (26). Thus, vomiting in alphavirus infection
350 may raise concerns for neuroinvasive disease. Additional symptoms positively associated
351 with alphavirus infection was arthralgia when compared to DENV, fever when compared to
352 ZIKV, and nausea when compared to CHIKV. These subtle differences highlight the
353 challenges for distinguishing between the arboviral infections based on clinical presentation
354 alone. Collectively, vomiting and the development of neurological symptoms and seizures
355 seem to be the most predictive symptoms of an encephalitic alphavirus infection when
356 compared to those occurring from other arbovirus infections endemic to Panama. However,
357 a major concern is that by the time a patient presents with neurological symptoms or
358 seizures they are already at risk for the development of severe encephalitic disease. This
359 highlights the need for improved diagnostic tools for the early detection of alphavirus
360 infections.

361

362 Our study has several limitations. First, clinical information on alphavirus infections were
363 documented using forms that might not capture detailed clinical and laboratory parameters
364 for both VEEV and MADV infections, as well as incomplete clinical data. Second, it is crucial
365 to note that encephalitic alphavirus cases often occur in rural or remote areas with limited
366 healthcare systems and resources, which could underestimate the number of cases. Third,
367 the limited sample size could impact the statistical power and conclusions, particularly for
368 less frequent symptoms. Fourth, the clinical outcome could be virus strain-dependent and
369 thus vary geographically. Finally, symptoms of encephalitic alphavirus infection were
370 compared with those of DENV, ZIKV, and CHIKV infections from Brazilian cohorts. Although
371 the genetic background and social conditions in Panama may differ from those in Brazil,
372 symptoms of DENV, ZIKV, and CHIKV infections appear to be similar across different
373 populations (27-30).

374

375 In summary, outbreaks of MADV and VEEV are expected to continue highlighting the
376 importance for continued surveillance efforts in Panama and other parts of Central and
377 South America. Our findings could serve as a valuable tool for clinical and epidemiological
378 decision-making in regions characterized by endemic arboviral circulation and limited
379 laboratory capacity. Human cases of febrile illness reporting vomiting, nausea, arthralgia,
380 and fever may help indicate acute alphavirus infection and should be monitored closely for
381 signs of neurological disease requiring prompt medical attention.

382

383

384

385 Tables and Figures

386

387 **Table 1. Socio-demographic characteristics of cases for whom samples were**
388 **submitted to GMI for encephalitic alphavirus testing from 1961 to 2023 (n=496) †.**

Characteristics	N (%)
Sex†	
	163
Female	(35.8)
Male	292 (64.2)
Age (years)*†	23.6 ± 19.7
Age group†	
0-5	98 (20.2)
6-20	159 (32.7)
≥21	229 (47.1)
Province	
Darien	319 (71.1)
Comarca	
Embera	32 (7.1)
Other provinces	98 (21.8)
VEEV	
Negative	400 (80.7)
Positive	96 (19.4)
MADV	
Negative	460 (92.7)
Positive	36 (7.3)


*Mean ± standard deviation.

† Some variables may total less than 496 due to missing data.

389


390

391




392
393
394
395
396
397

Figure 1. Laboratory algorithm for Madariaga and Venezuelan equine encephalitis diagnosis. Diagnostic algorithm used for two endemic encephalitic alphaviruses based on days since symptom onset.



398
399
400
401
402
403

Figure 2. Timeline of recorded a) VEEV and b) MADV important events in Panama. Timeline showing historical of VEEV and MADV events in, human cases, vectors, and animals in Panama over time from 1961 to 2023.



404

405

406

407

408


409

410

411

412

Figure 3. Map of recorded MADV and VEEV cases in Panama. Map showing the distribution of all MADV (green squares) and VEEV (red circles) cases reported in Panama from 1961-2023. MADV cases were only reported in the eastern Panama region, in the province of Darién. MADV cases detected outside Darién, in Chiriquí, Comarca Nābe Bugle and Herrera were reported in members of the border police working in the Darién Province, but at time of symptom onset these cases were detected in their home region.



413

414

415


Figure 4. Sign/symptom frequency heatmap by viral infection. Gray blocks denote missing data. * Several datasets from alphavirus cases in Panama and DENV, CHIKV and ZIKV infection cases from Brazil were used to provide more complete symptom data. [†] e.g.,

417

418

419

420




421

422 **Figure 5. Sign/symptom frequency heatmap by sex and viral infection.** [†] e.g., seizures,
 423 focal sensory and/or motor deficits, and diminished level of consciousness.

424

425



426

427 **Figure 6. Sign/symptom frequency heatmap by age and viral infection.** [†] e.g., seizures,
 428 focal sensory and/or motor deficits, and diminished level of consciousness.

429

430

431

432


433

434

435

436

437



438

439

Figure 7. Multivariable logistic regression analysis of associated symptoms of A) MADV vs VEEV infection, and combined encephalitic alphavirus infection versus, B) DENV infection, C) ZIKV infection and D) CHIKV infection. The red vertical line represented number 1, an odds ratio of 1 indicates that the odds of the event are the same in both groups.

443

444

445

446

Biographical Sketch

447

Dr. Luis Felipe Rivera, a primary care physician at the Gorgas Memorial Institute in Panama City, specializes in arbovirus surveillance and outbreak response. His primary focus includes diagnosing febrile diseases of unknown origin, tropical medicine, and conducting real time outbreak investigations.

451

452

Mr. Carlos Lezcano-Coba, an epidemiologist and virologist at the Gorgas Memorial Institute, is dedicated to arbovirus research. His primary interests lie in the epidemiology and ecology of emerging zoonotic diseases.

455

456

457

Acknowledgments

458

We wish to express appreciation to Betsy Dutary, Julio Cisneros, Evelia Quiroz and Mariana Garcia who worked to develop laboratory dengue surveillance system and alphavirus surveillance at GMI. We also thanks Kathryn Hanley from New Mexico State University for support with study design and funding. AV, LA and SL are members of the Sistema Nacional de Investigación (SNI), SENACYT, Panama. The views expressed in this work reflect the

462

463 results of research conducted by the authors and do not necessarily reflect the official policy
464 or position of the Department of Defense, the Navy, or the United States Government. DRS
465 is a U.S. Government employee. This work was prepared as part of her official duties. Title
466 17, U.S.C., § 105 provides that copyright protection under this title is not available for any
467 work of the U.S. Government. Title 17 U.S.C., § 101 defines a U.S. Government work as
468 work prepared by a military Service member or employee of the U.S. Government as part of
469 that person's official duties.

470

471 **Funding Statement:**

472 This study was partially supported by the Armed Forces Health Surveillance Division
473 (AFHSD), Global Emerging Infections Surveillance (GEIS) Branch, ProMIS ID
474 P0052_23_NM awarded to DRS. JPC is funded by the Clarendon Scholarship from the
475 University of Oxford (grant number SFF1920_CB2_MPLS_1293647). This work was
476 supported by SENACYT, through the grant FID-2021-96 grant to JPC; the National Institute
477 of Allergy and Infectious Diseases, the National Institutes of Health (grant K08AI110528 to
478 JJW), and the Centers for Research in Emerging Infectious Diseases (CREID) Coordinating
479 Research on Emerging Arboviral Threats Encompassing the NEOTropics (CREATE-NEO)
480 1U01AI151807 grant awarded to NV and KAH by the National Institutes of Health (NIH) and
481 by the World Reference Center for Emerging Viruses and Arboviruses (NIH R24 AI120942 to
482 SCW). CAD was supported by the NIHR HPRU in Emerging and Zoonotic Infections, a
483 partnership between PHE, the University of Oxford, the University of Liverpool, and the
484 Liverpool School of Tropical Medicine (grant no. NIHR200907). WMS is supported by the
485 Global Virus Network fellowship and the NIH (AI12094) Global Virus Network fellowship,
486 Burroughs Wellcome fund (#1022448) and Wellcome Trust-Digital Technology Development
487 award (Climate Sensitive Infectious Disease Modelling (226075/Z/22Z)). MLN is a CNPq
488 Research Fellow, and it is supported by a FAPESP grant # 22/03645-1). BPD is a CNPq
489 Research Fellow. NRF acknowledges support from Bill and Melinda Gates Foundation
490 (INV034540), and Medical Research Council-Sao Paulo Research Foundation (FAPESP)
491 CADDE partnership award (MR/S0195/1 and FAPESP 18/14389-0). AYV acknowledges
492 Research Command, NCRADA-NMRC-20-10993.

493

494

495 **References**

496

- 497 1. Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW.
498 Epidemic arboviral diseases: priorities for research and public health. *Lancet Infect Dis.* 2017
499 Mar;17(3):e101-e6.
- 500 2. de Souza WM, de Lima STS, Simoes Mello LM, Candido DS, Buss L, Whittaker C, et
501 al. Spatiotemporal dynamics and recurrence of chikungunya virus in Brazil: an
502 epidemiological study. *Lancet Microbe.* 2023 May;4(5):e319-e29.
- 503 3. Weaver SC, Charlier C, Vasilakis N, Lecuit M. Zika, Chikungunya, and Other
504 Emerging Vector-Borne Viral Diseases. *Annu Rev Med.* 2018 Jan 29;69:395-408.
- 505 4. Weaver SC, Dalgarno, L., Frey, T., Huang, H., Kinney, R. *Togaviridae*. In: van
506 Regenmortel MHV, Fauquet, C.M., Bishop, D.H.L, et al., editor. *Virus Taxonomy:*
507 *Classification and Nomenclature of Viruses: Seventh Report of the International Committee*
508 *on Taxonomy of Viruses.* CA, USA: Academic Press; 2000. p. 879-89.
- 509 5. Carrera JP, Pitti Y, Molares-Martinez JC, Casal E, Pereyra-Elias R, Saenz L, et al.
510 Clinical and Serological Findings of Madariaga and Venezuelan Equine Encephalitis Viral
511 Infections: A Follow-up Study 5 Years After an Outbreak in Panama. *Open Forum Infect Dis.*
512 2020 Sep;7(9):ofaa359.

- 513 6. Zacks MA, Paessler S. Encephalitic alphaviruses. *Vet Microbiol.* 2010 Jan 27;140(3-
514 4):281-6.
- 515 7. Arrigo NC, Adams AP, Weaver SC. Evolutionary patterns of eastern equine
516 encephalitis virus in North versus South America suggest ecological differences and
517 taxonomic revision. *J Virol.* 2010 Jan;84(2):1014-25.
- 518 8. Carrera JP, Forrester N, Wang E, Vittor AY, Haddow AD, López-Vergès S, et al.
519 Eastern equine encephalitis in Latin America. *N Engl J Med.* 2013 Aug 22;369(8):732-44.
- 520 9. Carrera JP, Cucunubá ZM, Neira K, Lambert B, Pittí Y, Liscano J, et al. Endemic and
521 Epidemic Human Alphavirus Infections in Eastern Panama: An Analysis of Population-Based
522 Cross-Sectional Surveys. *Am J Trop Med Hyg.* 2020 Dec;103(6):2429-37.
- 523 10. Aguilar PV, Estrada-Franco JG, Navarro-Lopez R, Ferro C, Haddow AD, Weaver SC.
524 Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue
525 umbrella. *Future Virol.* 2011;6(6):721-40.
- 526 11. Disease Outbreak News; Geographical expansion of cases of dengue and
527 chikungunya beyond the historical areas of transmission in the Region of the Americas.
528 <https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON448>.
529 <https://www.who.int/emergencies/disease-outbreak-news/item/2023-DON448>: World Health
530 Organization; World Health Organization 23 March 2023.
- 531 12. Diaz Y, Chen-German M, Quiroz E, Carrera JP, Cisneros J, Moreno B, et al.
532 Molecular Epidemiology of Dengue in Panama: 25 Years of Circulation. *Viruses.* 2019 Aug
533 20;11(8).
- 534 13. Quiroz E, Aguilar PV, Cisneros J, Tesh RB, Weaver SC. Venezuelan equine
535 encephalitis in Panama: fatal endemic disease and genetic diversity of etiologic viral strains.
536 *PLoS Negl Trop Dis.* 2009 Jun 30;3(6):e472.
- 537 14. Colombo TE, Estofolete CF, Reis AFN, da Silva NS, Aguiar ML, Cabrera EMS, et al.
538 Clinical, laboratory and virological data from suspected ZIKV patients in an endemic
539 arbovirus area. *J Clin Virol.* 2017 Nov;96:20-5.
- 540 15. Tabosa TSN, S.; Teixeira, I.; Oliveira, S.; Rodrigues, M.; Sampaio, V.; Endo, P.
541 Clinical cases of Dengue and Chikungunya. *Mendeley Data.* 2021 16 Dec 2021;1.
- 542 16. Johnson KM, Shelokov A, Peralta PH, Dammin GJ, Young NA. Recovery of
543 Venezuelan equine encephalomyelitis virus in Panama. A fatal case in man. *Am J Trop Med
544 Hyg.* 1968 May;17(3):432-40.
- 545 17. Franck PT, Johnson KM. An outbreak of Venezuelan encephalitis in man in the
546 Panama Canal Zone. *Am J Trop Med Hyg.* 1970 Sep;19(5):860-5.
- 547 18. Kelsner RA. Equine encephalomyelitis in Panama. *Veterinary bulletin.* 1937:19-21.
- 548 19. Dietz WH, Jr., Galindo P, Johnson KM. Eastern equine encephalomyelitis in
549 Panama: the epidemiology of the 1973 epizootic. *Am J Trop Med Hyg.* 1980 Jan;29(1):133-
550 40.
- 551 20. Srihongse S, Galindo, P. The isolation of eastern equine encephalitis virus from
552 *Culex (Melanoconion) taeiopus* Dyar and Knab in Panama. *Mosquito News.* 1967;27:74-6.
- 553 21. Vittor AY, Armien B, Gonzalez P, Carrera JP, Dominguez C, Valderrama A, et al.
554 Epidemiology of Emergent Madariaga Encephalitis in a Region with Endemic Venezuelan
555 Equine Encephalitis: Initial Host Studies and Human Cross-Sectional Study in Darien,
556 Panama. *PLoS Negl Trop Dis.* 2016 Apr;10(4):e0004554.
- 557 22. IOM, UNHCR call for stronger response in the Americas as half a million people
558 cross the Darien jungle. [https://www.unhcr.org/news/press-releases/iom-unhcr-call-stronger-
559 response-americas-half-million-people-cross-
560 darien?_kx=U3zIQO_vUUG98d0EF66fww2aW5M57VP6uiPJstEaeUk%3D.TQ4w2a](https://www.unhcr.org/news/press-releases/iom-unhcr-call-stronger-response-americas-half-million-people-cross-darien?_kx=U3zIQO_vUUG98d0EF66fww2aW5M57VP6uiPJstEaeUk%3D.TQ4w2a).
561 [https://www.unhcr.org/news/press-releases/iom-unhcr-call-stronger-response-americas-half-
562 million-people-cross-
563 darien?_kx=U3zIQO_vUUG98d0EF66fww2aW5M57VP6uiPJstEaeUk%3D.TQ4w2a](https://www.unhcr.org/news/press-releases/iom-unhcr-call-stronger-response-americas-half-million-people-cross-darien?_kx=U3zIQO_vUUG98d0EF66fww2aW5M57VP6uiPJstEaeUk%3D.TQ4w2a); United
564 Nations Refugee Agency 7 December 2023.
- 565 23. Carrera JP, Arauz D, Rojas A, Cardozo F, Stittleburg V, Morales Claro I, et al. Real-
566 time RT-PCR for Venezuelan equine encephalitis complex, Madariaga, and Eastern equine

- 567 encephalitis viruses: application in human and mosquito public health surveillance in
568 Panama. *J Clin Microbiol.* 2023 Dec 19;61(12):e0015223.
- 569 24. Reyna RA, Weaver SC. Sequelae and Animal Modeling of Encephalitic Alphavirus
570 Infections. *Viruses.* 2023 Jan 28;15(2).
- 571 25. Ronca SE, Dineley KT, Paessler S. Neurological Sequelae Resulting from
572 Encephalitic Alphavirus Infection. *Front Microbiol.* 2016;7:959.
- 573 26. Kumar G, Kalita J, Misra UK. Raised intracranial pressure in acute viral encephalitis.
574 *Clin Neurol Neurosurg.* 2009 Jun;111(5):399-406.
- 575 27. Asish PR, Dasgupta S, Rachel G, Bagepally BS, Girish Kumar CP. Global
576 prevalence of asymptomatic dengue infections - a systematic review and meta-analysis. *Int J*
577 *Infect Dis.* 2023 Sep;134:292-8.
- 578 28. de Lima Cavalcanti TYV, Pereira MR, de Paula SO, Franca RFO. A Review on
579 Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development. *Viruses.*
580 2022 May 5;14(5).
- 581 29. Harapan H, Michie A, Sasmono RT, Imrie A. Dengue: A Minireview. *Viruses.* 2020
582 Jul 30;12(8).
- 583 30. Plourde AR, Bloch EM. A Literature Review of Zika Virus. *Emerg Infect Dis.* 2016
584 Jul;22(7):1185-92.
- 585

